Drug Trial Radar · NCT04150887
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Actual
Start
Dec 23, 2019
Primary completion
May 15, 2027
Study completion May 15, 2027
Sponsor
- Lead sponsor
- OncoVerity, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- argenx; Janssen Research & Development, LLC
- First posted
- Nov 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).
Conditions
- Leukemia, Myeloid, Acute
Interventions
CusatuzumabDrug
Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
AzacitidineDrug
Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
VenetoclaxDrug
Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and Severity of Adverse Events (AEs), Laboratory Abnormalities, and Physical Exam Findings as a Measure of SafetyTime frame: Up to 42 months
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Norton Cancer Institute
Louisville, Kentucky
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Roswell Park Cancer Institute
Buffalo, New York
Weill Cornell Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of Rochester
Rochester, New York
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Vermont
Burlington, Vermont
Wisconsin Medical Center
Milwaukee, Wisconsin
Tom Baker Cancer Centre
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
University of Toronto
Toronto, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Universitaetsklinik Hamburg-Eppendorf
Hamburg, Germany
Universitaetsklinikum Leipzig
Leipzig, Germany
Klinikum der Universitaet Muenchen
München, Germany
Szpital Uniwersytecki w Krakowie
Krakow, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
Lodz, Poland
Instytut Hematologii i Transfuzjologii
Warsaw, Poland
INSELSPITAL, Universitätsspital Bern
Bern, Switzerland
Kantonsspital St.Gallen
Sankt Gallen, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.